GemVax and Samsung Pharm has launched its pancreatic cancer vaccine in Korea for the first time in the world

Published: 2015-05-04 13:42:46

Updated: 2015-05-04 13:42:46

The GemVax’s pancreatic cancer vaccine, Liavax(code name: GV1001), has been acquired the final sale approval from the Ministry of Food and Drug Safety.

Liavax, a pharmaceutical product approved for the 21^st time as a pancreatic cancer treatment from the Ministry of Food and Drug Safety on the last September, has been approved to manufacture and sell through its affiliated company, Samsung Pha...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.